Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.27
0.2 (0.3%)
Market Cap: 12.82 Bil
Enterprise Value: 12.45 Bil
PE Ratio: 40.28
PB Ratio: 2.37
GF Score: 69/100 Biomarin Pharmaceutical Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020 / 03:45PM GMT
Release Date Price:
$78.36
(+3.60%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome, everyone, to the Bank of America London Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And also, I have Aspen Mori from my team on the line as well.
So welcome, everyone, and we're thrilled to have for this session, BioMarin speaking. And we have with us, CEO, J.J. Bienaimé. And we also have President of Worldwide R&D, Hank Fuchs. Welcome, guys.
Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO
©,-&
Yes. Maybe just to kick things, you forgot Brian. It's Brian Mueller.
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Sorry, Brian, I'm sorry.
Brian R. Mueller;Geoffrey Christopher Meacham
BioMarin Pharmaceutical Inc. - Executive VP & CFO;BofA Merrill Lynch,
No worries.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot